Original ArticlesCross Validation of the Current Opioid Misuse Measure to Monitor Chronic Pain Patients on Opioid TherapyButler, Stephen F. PhD*; Budman, Simon H. PhD*; Fanciullo, Gilbert J. MD†; Jamison, Robert N. PhD‡Author Information *Inflexxion, Inc., Newton ‡Department of Anesthesia and Psychiatry, Pain Management Center, Brigham & Women's Hospital, Boston, MA †Department of Anesthesiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH Supported in part by grants (DA015617, Butler PI; DA024298, Jamison, PI) from the National Institutes of Health, Bethesda, MD and by an unrestricted grant to Inflexxion, Inc. from Endo Pharmaceuticals, Chadds Ford, PA. Reprints: Robert N. Jamison, PhD, Department of Anesthesia and Psychiatry, Pain Management Center, Brigham and Women's Hospital, Boston, MA 02115 (e-mail: [email protected]). Received for publication January 6, 2010; revised April 9, 2010; accepted April 29, 2010 The Clinical Journal of Pain: November 2010 - Volume 26 - Issue 9 - p 770-776 doi: 10.1097/AJP.0b013e3181f195ba Buy Metrics Abstract Objectives The Current Opioid Misuse Measure (COMM) is a self-report measure of risk for aberrant medication-related behavior among persons with chronic pain who are prescribed opioids for pain. It was developed to complement predictive screeners of opioid misuse potential and improve a clinician's ability to periodically assess a patient's risk for opioid misuse. The aim of this study was to cross-validate the COMM with a sample of chronic noncancer pain patients. Methods Two hundred and twenty-six participants prescribed opioids for pain were recruited from 5 pain management centers in the United States. Participants completed the 17-item COMM and a series of self-report measures. Patients were rated by their treating physician, had a urine toxicology screen, and were classified on the Aberrant Drug Behavior index. Results The reliability and predictive validity in this cross validation as measured by the area under the curve (AUC) were found to be highly significant (AUC=0.79) and not significantly different from the AUC obtained in the original validation study (AUC=0.81). Reliability (coefficient α) was 0.83, which is comparable to the 0.86 obtained in the original sample. Discussion Results of the cross validation suggest that the psychometric parameters of the COMM are not based solely on unique characteristics of the initial validation sample. The COMM seems to be a reliable and valid screening tool to help detect current aberrant drug-related behavior among chronic pain patients. © 2010 Lippincott Williams & Wilkins, Inc.